Adial enters $5M equity purchase agreement with Alumni Capital, terminates prior deal

ADIAL PHARMACEUTICALS, INC.

Company can sell up to $5M (option to $10M) of common stock to Alumni Capital at 97% of VWAP, with $0.55/share floor.
Issued 68,807 commitment shares as consideration; prior May 2023 agreement terminated.
Sales at Company's discretion; proceeds for strategic opportunities, working capital, general corporate purposes.
Agreement runs through Dec 31, 2026; Company can terminate on 10 days' notice.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.